Matthew Riordan

Octapharma AG develops, produces and sells plasma related products for treatment in coagulation disorders and immune diseases. The firm's products include virus-inactivated plasma for transfusion and fractionation products such as coagulation Factors VIII & IX for the treatment of haemophilia, von Willebrand Factor concentrate, prothrombin complex concentrate and immunoglobulins. Octapharma was founded in 1983 and is headquartered in Lachen, Switzerland.

Octapharma SAS manufactures pharmaceutical products. The company was founded on October 9, 1991 and is headquartered in Lingolsheim, France.

Octapharma AB manufactures and distributes pharmaceutical products. Its products used for treatment in coagulation disorders, immune disease, and intensive care and emergency medicine. The company operates as a subsidiary of Octapharma AG. Octapharma was founded in 1997 and is located in Stockholm, Sweden.

Octapharma GmbH specializes in the development and manufacture of preparations from human plasma. It focuses on virus-inactivated drugs for the treatment of diseases in the fields of immunology, hemophilia and Iten sivmedizin. The company was founded in 1983 and is headquartered in Langenfeld, Germany.

Part of Octapharma AG, Octapharma Ltd. is a British company that manufactures human protein products. The company is based in Manchester, UK. Octapharma was founded in 1983.

Octapharma Nordic AB specializes in the production and distribution of plasma derivative. Its products are used for the treatment in coagulation disorders, immune disease and intensive care and emergency medicine. The company is headquartered in Stockholm, Sweden